Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Looking for liquidity in Germany

OXFORD - Facing a moribund trading environment, some of Germany's biggest biotech names hope to offer investors more liquidity by splitting their stocks. Evotec BioSystems AG (NMarkt:EVO) and Qiagen N.V. (NMarkt:QIA; QGENF) last week announced intentions to undertake share splits

Read the full 400 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers